The current stock price likely implies Botox declines, but we think the franchise can maintain healthy growth as a result of expansion of the market and limited price competition. Firms Likely to Have ...

An enduring medical aesthetics franchise, led by wrinkle-fighter Botox, is one of the key reasons AbbVie is shelling out $63 billion for Allergan. That drug has again pulled off a sales jump, though a ...

With a $63 billion merger nearing approval, AbbVie is counting on Allergan and its cash-cow Botox to boost sales—and that superstar could be a long-term winner. But not every drug in Allergan's stable ...

SANTA ANA, Calif. (CN) - Finding that a German company stole trade secrets, a federal judge blocked Merz Pharmaceuticals for 10 months from selling a botulinum-based product that competes with ...

Shares of Irvine-based Allergan Inc. jumped Monday as Wall Street got its first crack at the stock after word Friday that the company’s flagship Botox drug was approved as a treatment for migraine ...

For Allergan Inc., a subtle offense has proved the best defense in the court of public opinion over Botox. Observers give the Irvine drug maker good marks for its strategy in support of Allergan’s ...

A federal jury July 18 said Revance Therapeutics' skin medication infringed on patents for anti-wrinkle treatment Botox and owes AbbVie-owned Allergan $56 million. The lawsuit, filed by Ireland-based ...